Výsledky vyhledávání

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

Autor: Douglas Cunningham, D. Ward, Mamta K. Jain, Faiza Ajana, Magda Opsomer, Anita Rachlis, Sharon Walmsley, Frank A. Post, Anders Blaxhult, Amanda Clarke, M. J. Galindo, Marcel Stoeckle, P.-M. Girardy, Karam Mounzer, David Shamblaw, U. F. Bredeek, L. Bhatti, J. J. Eron, Andrew Ustianowski, Mar Gutierrez, John Jezorwski, Javier O Morales-Ramirez, Antonio Rivero, M.A. Johnson, Gatell Jm, Erika Van Landuyt, Stéphane De Wit, A. Wilkin, Laurent Cotte, Cheryl McDonald, D. Murphy, Cynthia Brinson, Romana Petrovic, Olayemi Osiyemi, J. de Vente, I. Poizot-Martin, Juan Berenguer, Robin Dretler, J. Bailey, B. Rashbaum, Moti Ramgopal, A. Scribner, Yazdan Yazdanpanah, Eric Florence, A. Piekarska, Brian Gazzard, Chloe Orkin, W. Halota, Gary Richmond, Jacques Reynes, C. Ricart, C. Lucasti, Ignacio Pérez-Valero, Jason Brunetta, S. Shafran, Daniel Podzamczer, Franco Antonio Felizarta, Claudia Martorell, F. Post, Peter Ruane, Edwin DeJesus, J. Portilla Sogorb, C. Orkin, K. Tashima, Federico Pulido, Bernard Vandercam, F. Pulido, José L. Casado, Christine Katlama, Kimberley Brown, J Gasiorowski, A. Witor, Joseph J. Eron, Brian Conway, Andri Rauch, Jose R. Arribas, Michel Moutschen, H. Olivet, A. Scarsella, Leo Flamholc, A. Horban, D. Cunningham, Ronald Nahass, Félix Gutiérrez, G. Huhn, W.K. Henry, A. Thalme, S De Wit, Jan Fehr, Debbie Hagins, José Antonio Iribarren, J.-M. Molina, S. Henn, F Raffi, Juan A. Pineda, Marina B. Klein, Eugenia Negredo, Hernando Knobel, J. Slim, P. Benson, L. Waters, E. Teicher, Linos Vandekerckhove, Craig A. Dietz, Magnus Gisslén, Joel E. Gallant, J. Gathe, P. Shalit, D. Prelutsky, G. Voskuhl, D. Rey, E. Van Wijngaerden, Anthony Mills, Erkki Lathouwers, Carl J. Fichtenbaum, I. Brar, Gordon Crofoot, Veerle Hufkens, I. Santos Gil

Publikováno v: Antiviral Research
Antiviral Research, Elsevier Masson, 2019, 170, pp.104543. ⟨10.1016/j.antiviral.2019.104543⟩
ANTIVIRAL RESEARCH
Antiviral Research, 2019, 170, pp.104543. ⟨10.1016/j.antiviral.2019.104543⟩
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Dipòsit Digital de la UB
Universidad de Barcelona
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
Antiviral research, Vol. 170, p. 104543 [1-11] (2019)

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in EMERALD (NCT02269917). Virologically-suppressed, HIV-1-positive treatment-experienced adults (previous non-darunavir virologic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::017eb51bc97390ae19e12fb2aea5fdc8
http://hdl.handle.net/2445/171213

Zobrazit plný text záznamu

Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial

Autor: David Shamblaw, Olayemi Osiyemi, Anders Blaxhult, Amanda Clarke, M. J. Galindo, Edwin DeJesus, Mamta K. Jain, Craig A. Dietz, Juan Berenguer, Jacques Reynes, E. Teicher, A Horban, Simon Vanveggel, D. Cunningham, C. Ricart, Erkki Lathouwers, Carl J. Fichtenbaum, Anita Rachlis, E Negredo, A. Witor, Joseph Gathe, S De Wit, Debbie Hagins, E. Van Wijngaerden, Eric Florence, Peter Ruane, Anthony Mills, J. Bailey, Karen T. Tashima, Gary Richmond, J. de Vente, Jihad Slim, Ronald Nahass, G. Huhn, Jean-Michel Molina, Moti Ramgopal, D. Murphy, W. Halota, A. Thalme, Frank A. Post, Mdm Gutierrez, Jan Fehr, Cheryl McDonald, Jose R. Arribas, Doug Ward, Laurent Cotte, D. Rey, Magda Opsomer, Sharon Walmsley, Isabelle Poizot-Martin, Cynthia Brinson, L. Waters, G. Voskuhl, C Orkin, Faiza Ajana, Antonio Rivero, Erika Van Landuyt, Marcel Stoeckle, H. Olivet, L. Bhatti, J. J. Eron, J. Gathe, P. Shalit, Ignacio Pérez-Valero, Daniel Podzamczer, Jason Brunetta, Romana Petrovic, B. Rashbaum, Leo Flamholc, David James Prelutsky, W.K. Henry, José Antonio Iribarren, J.-M. Molina, Margaret A. Johnson, M Moutschen, Claudia Martorell, Karam Mounzer, Anthony John Scarsella, J Gasiorowski, Robin Dretler, Magnus Gisslén, Andrew Ustianowski, Chloe Orkin, C. Lucasti, Joel E. Gallant, Bernard Vandercam, Aimee M. Wilkin, Juan A. Pineda, Gatell Jm, Joseph J. Eron, P-M Girard, Indira Brar, Linos Vandekerckhove, Yazdan Yazdanpanah, F Raffi, A. Scribner, Brian Gazzard, Franco Antonio Felizarta, Marina B. Klein, Eugenia Negredo, Hernando Knobel, Gordon Crofoot, Stephen D. Shafran, U. F. Bredeek, Veerle Hufkens, Javier O Morales-Ramirez, P. Benson, I. Santos Gil, A. Piekarska, Brian Conway, Andri Rauch, J. Portilla Sogorb, Federico Pulido, Félix Gutiérrez, S. Henn, José L. Casado, Christine Katlama

Publikováno v: The lancet. HIV. 5(1)

Simplified regimens with reduced pill burden and fewer side-effects are desirable for people living with HIV. We investigated the efficacy and safety of switching to a single-tablet regimen of darunavir, cobicistat, emtricitabine, and tenofovir alafe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52a3f8b388e89ebb2d86e841a5c32131
https://pubmed.ncbi.nlm.nih.gov/28993181

Zobrazit plný text záznamu

Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE

Autor: Katia Boven, L Mohapi, Keikawus Arastéh, P Kumar, William R. Short, J Gathe, J Gold, Herta Crauwels, S Hodder, Simon Vanveggel, J De Wet

Publikováno v: HIV Medicine. 13:406-415

Objectives A week 48 efficacy and safety analysis with respect to gender and race was conducted using pooled data from the phase III, double-blind, double-dummy efficacy comparison in treatment-naive, HIV-infected subjects of TMC278 and efavirenz (EC

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::227d681b0a783453bd8b3a8a751230f1
https://doi.org/10.1111/j.1468-1293.2012.00991.x

Zobrazit plný text záznamu

Beyond Efficacy: The Impact of Combination Antiretroviral Therapy on Quality of Life

Autor: Paul E. Sax, J. Gathe

Publikováno v: AIDS Patient Care and STDs. 19:563-576

Combination antiretroviral therapy (ART) with two nucleoside reverse transcriptase inhibitors (NRTIs) plus a protease inhibitor (PI) significantly improved the prognosis of patients with HIV. Nevertheless, the usefulness of the first PIs was sometime

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4bfb0a310185800567cb8693e21d7e9
https://doi.org/10.1089/apc.2005.19.563

Zobrazit plný text záznamu

VERxVE 144 week results: nevirapine extended-release (NVP XR) QD versus NVP immediate-release (IR) BID with FTC/TDF in treatment-naïve HIV-1 patients

Autor: C Brinson, J Bogner, M Nelson, D Podzamczer, A Quinson, M Drulak, J Gathe

Publikováno v: Journal of the International AIDS Society. 15

Background : Here we report 96- and 144-week follow-up data from VERxVE, which demonstrated that NVP XR (400 mg QD) was non-inferior to NVP IR (200 mg BID), each on a backbone of emtricitabine/tenofovir at 48 weeks. Methods : VERxVE was a double-blin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fd5b786aac6a3fcf624a0a168cc07e8f
https://doi.org/10.7448/ias.15.6.18236

Zobrazit plný text záznamu

Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE

Autor: S, Hodder, K, Arasteh, J, De Wet, J, Gathe, J, Gold, P, Kumar, L, Mohapi, W, Short, H, Crauwels, S, Vanveggel, K, Boven

Publikováno v: HIV medicine. 13(7)

A week 48 efficacy and safety analysis with respect to gender and race was conducted using pooled data from the phase III, double-blind, double-dummy efficacy comparison in treatment-naïve, HIV-infected subjects of TMC278 and efavirenz (ECHO) and TM

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::2b5d28df500880d283973520a7ef52c9
https://pubmed.ncbi.nlm.nih.gov/22416849

Zobrazit plný text záznamu

Optimizing care for African-American HIV-positive patients

Autor: Joseph Nkwanyou, Helena Kwakwa, Andre Brutus, Diana Williamson, Ronald Cathcart, J. Gathe, Robert Scott, William Johnson, Carlos Page, Luther A. Virgil, Anita Vaughn, Kimberly Y. Smith, Wilbert C. Jordan

Publikováno v: AIDS patient care and STDs. 17(10)

The African-American community has been disproportionately affected HIV/AIDS, as noted by higher reported rates of HIV infection, higher proportion of AIDS cases, and more deaths caused by complications of AIDS than whites and other ethnic groups. In

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54572f254b9a0d55573295152eb1601f
https://pubmed.ncbi.nlm.nih.gov/14588093

Zobrazit plný text záznamu

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial

Autor: S, Staszewski, P, Keiser, J, Montaner, F, Raffi, J, Gathe, V, Brotas, C, Hicks, S M, Hammer, D, Cooper, M, Johnson, S, Tortell, A, Cutrell, D, Thorborn, R, Isaacs, S, Hetherington, H, Steel, W, Spreen

Publikováno v: JAMA. 285(9)

Abacavir, a nucleoside analogue, has demonstrated suppression of human immunodeficiency virus (HIV) replication alone and in combination therapy. However, the role of abacavir in a triple nucleoside combination regimen has not been evaluated against

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::0827a360788db6f0f51973dbe9fe77ba
https://pubmed.ncbi.nlm.nih.gov/11231752

Zobrazit plný text záznamu

Hormone replacement therapy for African American women: missed opportunities for effective intervention

Autor: W K, Nicholson, A F, Brown, J, Gathe, K, Grumbach, A E, Washington, E J, Pérez-Stable

Publikováno v: Menopause (New York, N.Y.). 6(2)

Because of the potential benefits and risks of hormone replacement therapy (HRT), information about the efficacy of HRT in different groups of women is important to patients and providers. The objectives of this study were to review the evidence on t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::02ea59056a13995dfeaed81119df61b2
https://pubmed.ncbi.nlm.nih.gov/10374222

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání